...
首页> 外文期刊>British Journal of Cancer >123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer
【24h】

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer

机译:大肠癌患者体内123I标记的血管活性肠肽受体显像

获取原文

摘要

Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [123I]VIP. In this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with histologically verified colorectal cancer underwent scanning by means of [123I]VIP (1 microg, approximately 150 MBq). Thirteen patients were free of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and 6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine physicians in a blinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with [123I]VIP. Negative VIP scans were obtained in all 13 patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to conventional radiological methods.
机译:最近的研究表明,各种胃肠道肿瘤表达大量的血管活性肠肽(VIP)受体。基于这些观察,我们开发了使用[123I] VIP作为放射性配体的受体闪烁显像。在我们机构进行的初步研究表明,通过[123I] VIP可以可视化各种胃肠道腺癌的潜力。在本文中,我们现在报告80例大肠腺癌连续患者获得的结果。通过[123I] VIP(1微克,约150 MBq)对80例经组织学证实为大肠癌的连续患者进行了扫描。彻底切除Dukes'C癌后,有13例患者无肿瘤,有8例为原发性,14例为局部复发性肿瘤,但无转移。十名患者患有局部复发性疾病以及肝,肺或淋巴结转移。 35名患者出现了局限于器官转移的疾病(即肝,肺或淋巴结)。原发性或复发性肿瘤的大小在3至6厘米之间,转移灶的直径在1至13厘米之间。两名核医学医师以盲法独立评估了扫描结果,然后将结果与不超过4周的计算机断层扫描(CT)扫描进行了比较。 [123I] VIP可以对八种原发性癌症中的七种(87%)和24种中的21种(82%)进行成像。在所有13例已经治愈了癌症的患者中获得了阴性VIP扫描。所有具有淋巴结转移的患者均显示阳性VIP扫描(四分之四),并且在28例肝转移患者中有25例(89%)和在三分之二的肺转移患者中均获得了阳性扫描。在4例复发性癌症患者中,VIP扫描表明CT之前存在疾病,而在2例患者中,可以确定疤痕组织的诊断,而不是CT建议的直肠癌的局部复发。我们得出结论,[123I] VIP受体扫描是一种对大肠癌进行放射成像的灵敏方法,具有为常规放射学方法提供有价值的附加信息的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号